Three Bridge Wealth Advisors LLC Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Three Bridge Wealth Advisors LLC purchased a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 22,371 shares of the company’s stock, valued at approximately $120,000.

Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after buying an additional 102,869 shares during the period. Jane Street Group LLC bought a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth about $265,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after purchasing an additional 53,809 shares during the period. State Street Corp lifted its stake in shares of Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after purchasing an additional 57,943 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $74,000. 46.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CRVS. Oppenheimer lifted their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. Finally, StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Stock Up 1.6 %

NASDAQ CRVS opened at $5.04 on Thursday. Corvus Pharmaceuticals, Inc. has a 52 week low of $1.30 and a 52 week high of $10.00. The business has a 50 day moving average price of $5.74 and a 200-day moving average price of $5.96. The company has a market cap of $323.87 million, a price-to-earnings ratio of -5.42 and a beta of 1.07.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.